Mr. Krebs joined BI – Toronto as Associate Director, Brand Development in 2018, was promoted to New York Director, Brand Development in 2020 and promoted to President Toronto in 2022. During Devin’s time at Brand Institute, he has had vast pharmaceuticals experience, working on name development initiatives including Tetra Bio-Pharma’s corporate business unit (ENJOUCA), and several pharmaceutical brand names including oncology (DAURISMO, PIQRAY, RIXIMYO), endocrinology
(INCRELEX, RYBELSUS), immunology (RYALTRIS, ZEPOSIA), pain & inflammation (AVSOLA, SUVEXX), respiratory (ITULATEK), and hematology (INCLUNOX, TAVALISSE) therapeutic areas. Prior to joining BI, Devin worked for 4 years as an Account Manager at IMCD, a leading distributor of pharmaceutical products from manufacturers including BASF, DuPont, CP Kelco, Lubrizol, Shin-Etsu and Firmenich. In this role, he provided excipients and APIs for pharmaceutical formulations. He earned a B.Sc. in Medical Sciences from Brock University.
